Page images
PDF
EPUB

Royal Society of Medicine Services Limited
International Congress and Symposium Series

[merged small][merged small][merged small][merged small][graphic][merged small][merged small]

ROYAL SOCIETY OF MEDICINE SERVICES LIMITED

1 Wimpole Street, London WIM 8AE

Distributed by
OXFORD UNIVERSITY PRESS

Walion Street, Oxford OX2 6DP
London New York Toronto
Delhi Bombay Calcula Madras Karachi
Kuala Lumpur Singapore Hong Kong Tokyo
Nairobi Dar es Salaam Cape Town
Melbourne Auckland
and associated companies in
Beirut Berlin Ibadan Mexico City Nicosia
Oxford is a trade mark of Oxford University Press

Copyrighi 1986 by
ROYAL SOCIETY OF MEDICINE SERVICES LIMITED

All rights reserved. No part of this book may be reproduced in any form by photostat, microfilm. or any other means, without written permission from the publishers.

This publication is copyright under the Berne Convention and the International Copyright Convention. All rights reserved. Aparı from any fair dealing under the UK Copyright Act 1956, Pari 1, Section 7, no part of this publication may be reproduced, stored in a retrieval system or iransmilied in any form or by any means without the prior permission of the Honorary Editors, Royal Society of Medicine.

These proceedings are published by Royal Society of Medicine Services Lid with financial support from the sponsor. The contributors are responsible for the scientific content and for the views expressed, which are not necessarily those of the sponsor, of the editor of the series or of the volume, of the Royal Society of Medicine or of Royal Society of Medicine Services Lid. Distribution has been in accordance with the wishes of the sponsor bui a copy is available to any Fellow of the Society at a privileged price.

British Library Cataloguing in Publication Data
Further progress with gemfibrozil. — (International

congress and symposium series, ISSN 0142-2367;
no. 87)
1. Gemfibrozil
1. Wood, Clive II. Royal Society of Medicine
615'.718 RM666.64

ISBN 0-90595-816-0

Editorial and Production services by Fisher Duncan Lid, 10 Barley Mow Passage, London W4 4PH
Phototypeset by Dobbie Typesetting Service, Plymouth, Devon
Printed in Great Britain at the University Press, Oxford

Contributors

D. Canter MA, MB, ChB, FRCS

International Clinical Research, Warner-Lambert: Parke-Davis, Pontypool,
Gwent NP4 OYA, UK

B. Ek MD

Department of Medicine, University of Umeå, S-901 85. Umea,
Sweden

Helsinki Heart Study Ethical Committee

Albertinkatu 23A, PL228, 00121 Helsinki 12, Finland

S. Kaukola MD

First Department of Medicine, Helsinki University Central Hospital,
SF-00290, Helsinki 29, Finland

H. Meinertz MD

Department of Medicine B, Rigshospital DK-2100, Copenhagen 0,
Denmark

J. R. O'Brien DM, FRCP, FRCPath

Portsmouth District Pathology Service Central Laboratory, St Mary's
Hospital, Portsmouth, PO3 6AG, UK

8. Vessby MD

Department of Geriatrics, University of Uppsala, PO Box 12042, S-750,
Uppsala, Sweden

Contents

List of contributors

Influence of gemfibrozil on lipoprotein composition: triglyceride removal capacity and fatty acid composition of the plasma lipid esters

BENGT VESSBY, MERIKE BOBERG and HANS LITHELL .

1

Effect of gemfibrozil on some haematological parameters

J. R. O'BRIEN, M. D. ETHERINGTON, R. D. SHUTTLEWORTH, CHERYL M.
ADAMS, J. E. MIDDLETON and F. C. GOODLAND.

11

Effects of gemfibrozil on plasma lipoproteins in patients with
Type II hyperlipoproteinaemia and familial hypercholesterolaemia

HANS MEINERTZ.

15

Gemfibrozil increases HDL-cholesterol and apolipoprotein Aand A-Il concentrations in dyslipidaemic subjects

SIRKKA KAUKOLA, VESA MANNINEN, CHRISTIAN EHNHOLM and
MARJATTA MÄLKÖNEN

23

Augmentation of gemfibrozil-induced hypolipidaemia by psylliumbased fibre

BÖRJE EK, MARJATTA MÄLKÖNEN and VESA MANNINEN

31

Long-term treatment with gemfibrozil in male survivors of myocardial infarction

SIRKKA KAUKOLA, MARJATTA MÄLKÖNEN, PEKKA KOSKINEN and VESA
MANNINEN.

35

[ocr errors][merged small]

Long-term studies with gemfibrozil in Finland: an 8-year follow-up

DAVID CANTER

41

Safety as a factor in lipid-regulating primary prevention drug trials: the Helsinki Heart Study Interim Report

HELSINKI HEART STUDY ETHICAL COMMITTEE

51

« PreviousContinue »